Literature DB >> 791034

Human oral defenses against gram-negative rods.

F M Laforce, J Hopkins, R Trow, W L Wang.   

Abstract

Gram-negative rods are unusual pharyngeal isolates in normal man, which suggests the presence of effective oral defense mechanisms against these organisms. To understand this protection better, we studied the elimination of gram-negative rods from the mouth after gargle challenge. Suspensions of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (108 organisms per ml) were gargled by normal volunteers, and pharyngeal swabs for serial quantitative cultures were taken for 3 hours. Initial swabs yielded approximately 10(5) organisms. Bacterial counts rapidly decreased, and less than 1 per cent of the original inoculum was still recoverable 3 hours later. Studies of tongue, pharynx, and buccal mucosa samples showed the most rapid decrease in buccal mucosa samples and the slowest decrease in tongue swabs. To evaluate physical clearance, gargle challenges were performed using E. coli radiolabeled with technetium-99m. External counts of the oral cavity decreased rapidly, with 21.8, 14.7, 8.9, and 7.8 percent of the initial counts remaining at 30, 60, 120, and 180 min, respectively. Nonpiliated E. coli adhered poorly to buccal epithelial cells in vitro, in contrast to good adherence when piliated strains were tested. Despite these findings, no differences in radiolabel clearance was noted in vivo using piliated and nonpiliated E. coli for gargle challenges. Normal oral defenses against gram-negative rods are highly effective and seem to involve both physical clearance and local bactericidal activity.

Entities:  

Mesh:

Year:  1976        PMID: 791034     DOI: 10.1164/arrd.1976.114.5.929

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

Review 1.  Nosocomial pneumonia in children.

Authors:  R F Jacobs
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen.

Authors:  C P Stoutenbeek; H K van Saene; D R Miranda; D F Zandstra; D Langrehr
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 3.  Nosocomial pneumonia in patients in intensive care units.

Authors:  S D Podnos; G B Toews; A K Pierce
Journal:  West J Med       Date:  1985-11

4.  Attachment of bacteria to mammalian surfaces.

Authors:  B Sugarman
Journal:  Infection       Date:  1980       Impact factor: 3.553

5.  The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients.

Authors:  C P Stoutenbeek; H K van Saene; D R Miranda; D F Zandstra
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

Review 6.  The digestive tract in immunocompromised patients: importance of maintaining its resistance to colonization, especially in hospital in-patients and those taking antibiotics.

Authors:  D van der Waaij
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

7.  Effects of cancer chemotherapy on the human aerobic oropharyngeal flora.

Authors:  K W Renard; M Marling-Cason; R G Sheehan; P A Mackowiak
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

Review 8.  Aspiration and infection in the elderly : epidemiology, diagnosis and management.

Authors:  Masayuki Kikawada; Toshihiko Iwamoto; Masaru Takasaki
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

9.  Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.

Authors:  J R Rodríguez; C H Ramírez-Ronda; M Nevárez
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  Effect of decreased salivation and pH on the adherence of Klebsiella species to human buccal epithelial cells.

Authors:  G H Ayars; L C Altman; M D Fretwell
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.